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Abstract
Three independent studies of tight glucose control were recently
stopped prematurely due to an excess mortality in the intensive
treatment arm. This commentary briefly discusses the potential
mechanisms and reminds the potential benefits of physiological
stress hyperglycemia.
In the closed world of intensive care medicine, the wave of
enthusiasm triggered by the Leuven study [1] – which
reported a dramatic improvement in the vital outcome of
surgical intensive care unit patients after restoration of
normoglycaemia by intensive insulin therapy – progressively
vanished after the failure of several trials conducted to
confirm these results in other institutions or settings.
Three different and independent multicentre studies designed
to compare the outcome of patients randomised to a therapy
designed to lower blood glucose versus conventional
treatment were halted very recently, because of an increase
in the rate of hypoglycaemia without a benefit in terms of
mortality. More worrisome, a nonsignificant but consistent
increase of the 28-day mortality was found in the first two
trials conducted in intensive care – the Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis (VISEP)
study [2] and the GluControl study [3]. In both trials, in which
537 septic patients and 1,101 critically ill patients were
enrolled, intensive insulin therapy was titrated to reach blood
glucose of 80–110 mg/dl (the normoglycaemic range). The
results of the even larger Normoglycaemia in Intensive Care
Evaluation and Survival Using Glucose Algorithm Regulation
study [4] are awaited for the end of 2008, and will probably
provide important additional information on the effects of
intensive insulin therapy titrated to restore and maintain
normoglycaemia in critically ill patients.
An announcement was recently made regarding a large
National Institutes of Health-sponsored trial conducted in
more than 10,000 outpatients with type II diabetes and at
risk for heart attack and stroke followed in 77 North
American centres [5]. The Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study was halted prematurely,
however, because of an excess mortality in the intensive
treatment arm. The sustained lowering of blood glucose was
reflected by a fall below 6% of the percentage of
glycosylated haemoglobin in the intensive treatment group,
as planned per protocol.
Even though short-term and long-term mortality can hardly be
integrated, these three major studies provide a consistent
sound alarm signal against the concept of lowering blood
glucose as a simple risk-free, harmless and potentially life-
saving therapeutic modality. Interestingly enough, the consis-
tency of these findings is supported by the use of different
therapeutic strategies – intravenous insulin in the VISEP and
GluControl trials, and oral medications or subcutaneous
insulin in the ACCORD study.
In fact, the use of the term normoglycaemia itself might be
misleading when the range of normal blood glucose was
defined in fasting healthy individuals and is mainly used to
exclude the diagnosis of diabetes. In critically ill patients or in
diabetic patients, such a blood glucose range (80–110 mg/dl)
may not be normal, or desirable. The possible reasons for the
increased mortality after lowering of blood glucose by
intensive treatment can only be speculated, prior to a more
detailed analysis of the causes of deaths. Nonetheless,
inappropriately low glucose levels can induce a shortage of
the provision of glucose, the predominant source of energy
useable by the myocardium during ischaemia, and neuro-
glycopenia in cases of cerebral injury [6,7]. In both situations,
the outcome of patients can be directly endangered.
The human body has actually developed physiological meta-
bolic responses  to survive stressful situations. Increased
glucose turnover, and hence increased blood glucose concen-
trations, plays a major role in this response. We should
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probably bear these adaptive mechanisms in mind when
developing new therapeutic strategies.
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